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Mutations in the BRAF-gene are found in benign and malignant melanocytic lesions, 490% being a V599E mu-
tation. This mutation results in constitutively active kinase function and increased colony formation in vitro. The
biological impact of this mutation in vivo is still debated. To address this question, we used our digital epilumi-
nescence image archive and retrospectively selected 49 melanocytic lesions, which did not meet the criteria of
melanoma at the initial presentation. Mean 12 months later these lesions were excised because of increased size or
changed structure and BRAFV599E mutations were analyzed. Among 36 growing lesions, BRAFV599E mutations were
found in 16 (11 melanomas and 5 nevi). Among 13 lesions with structural changes, BRAFV599E mutations were
found in 4 (3 melanomas and 1 nevus). Thirty-ﬁve randomly selected additional lesions with no changes during
follow-up served as controls, all nevi by histology, and two of them showed a BRAFV599E mutation. Statistics
revealed odds for the presence of the BRAFV599E mutation being seven times higher in lesions with structural
changes and 13 times higher in growing lesions as compared with lesions without changes. This raises the
question if the V599E mutation determines lesions at risk developing into melanoma and if not, what are the
mechanisms controlling growth stop in benign lesions?
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Melanoma is a highly malignant tumor with a constantly
rising incidence. In the United States alone it had been es-
timated that more than 7000 people will have died from
melanoma in 2003. To reduce mortality, early recognition of
melanoma is required. Clinical parameters indicative for
early melanoma include lesion growth and/or the occur-
rence of structural changes during follow-up, which can be
identified by digital epiluminescence microscopy (DELM).
Through photo-documentation, changed appearances of
melanocytic lesions at follow-up visits are detected and le-
sions are then subjected to surgical excision and histolog-
ical evaluation. This technique has reduced the frequency of
unnecessary excisions and improved recognition of early
melanoma (Kittler et al, 2000). Still a considerable number of
lesions thereby excised were benign, however, by histology
in spite of the observed growth and/or the occurrence of
structural changes within a short follow-up period of mean
12 months. This raises the question about factors inducing
this onset of rapid growth of a melanocytic lesion.
In melanoma, possibilities are numerous ranging from
environmental or endocrine factors to occurrence of spon-
taneous somatic mutations. In nevi, hormonal factors (e.g.,
during pregnancy) are known to promote growth. With re-
gard to mutations in nevi, current knowledge is limited. Re-
cently, mutations in the BRAF gene have been described
but the biological impact of this finding is still under debate
(Davies et al, 2002).
BRAF is a member of the raf gene family encoding for a
cytoplasmic serine/threonine kinase, which signals in the
RAF-MAP kinase pathway and mediates cell proliferation
and differentiation (Davies et al, 2002; Mercer and Pritchard,
2003). About 70% of melanomas and a varying number of
benign melanocytic lesions (ranging from 10% to 73%)
showed somatic missense mutations within the BRAF gene.
The mutation T1796A leading to a substitution (V599E) ac-
counted for 90% of all identified BRAF mutations (Davies
et al, 2002; Dong et al, 2003; Pollock et al, 2003; Uribe et al,
2003). This mutation leads to RAS-independent autoactiva-
tion of the BRAF kinase with subsequent stimulation of the
downstream kinases and transcription factors. Overexpres-
sion of this mutated kinase is responsible for an increased
transformatory potential in NIH3T3 cells (Davies et al, 2002).
It was thus the aim of this study to test the possibility that a
sudden onset of melanocytic lesion growth correlates with
the occurrence of BRAFV599E mutations.
Results
We selected 49 melanocytic lesions that were all small
(Table Ia; no differences between groups) and not suspicious
for melanoma at the initial visit. They were routinely photo-
documented at the initial presentation and showed enlarge-
ment or structural alterations at the second visit (Table Ia,Abbreviations: DELM, digital epiluminiscence microscopy
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examples given in Fig 1). Following excision at the second
visit, 24 were classified as melanomas and 25 as nevi by
histology. These 49 lesions and 35 additional control lesions
with no changes by DELM during the follow-up were sub-
jected to BRAF genotyping (Fig 2).
In 15 of 24 melanomas, in five of 25 nevi with changes,
and in two of 35 control lesions, a BRAFV599E mutation was
detected (Table Ib).
By subgrouping lesions—regardless of their dignity—into
lesions with growth, with structural changes and those
without changes, the BRAF mutation was significantly as-
sociated with rapid growth. The odds for a growing me-
lanocytic lesion to be positive for the BRAFV599E mutation
was 13 times higher and for lesions with structural changes
seven times higher as compared with lesions without
changes (po0,001; Table Ic).
By subgrouping lesions according to their anatomical
localization, we found 6 of BRAFV599E and 18 of BRAFwt
lesions situated in chronic sun exposed areas (face, neck,
distal parts of limbs). Sixteen BRAFV599E and 42 BRAFwt
lesions were located in skin with chronic intermittent sun
exposure. Two BRAFwt lesions were located in glabrous
skin. These data did not reveal a correlation between sun
exposure and the probability of BRAFV599E mutation as re-
ported recently by Maldonado et al (2003), but our study
was not designed to address this issue.
By subgrouping lesions according to histopathological
criteria, the BRAFV599E mutation was seen in two of seven
junctional nevi, in four of 26 compound nevi and in one of six
dermal nevi. In malignant lesions, eight of 12 melanomas in
situ and seven of 11 invasive melanomas were positive for
the BRAFV599E mutation. Statistical analysis did not reveal
significant differences, but for such an evaluation, sample
size is too small.
Discussion
This study analyzed melanocytic lesions, which were small
and not suspicious for melanoma at the first visit, but
showed growth or structural changes within a short obser-
vation period of mean 12 mo. In these lesions, the prob-
ability to find BRAFV599E mutation was 13 times higher as
compared with lesions without changes. Although BRAF
mutations were clearly more frequent in melanomas as
compared with nevi, a finding which has also been reported
by others (Dong et al, 2003; Uribe et al, 2003; Yazdi et al,
2003), the fact remains that in growing nevi there was a
striking high incidence of the BRAF mutation as compared
with nevi without growth. This raises two important ques-
tions:
First question: are nevi with BRAFV599E mutations pre-
cursor lesions of melanoma, which yet do not meet diag-
nostic criteria of malignancy?
The BRAFV599E mutation has first been identified in short
time cultures of melanoma explants. This mutation is
thought to be somatic (Meyer et al, 2003a) and this is also
supported by results from 8 of our patients. In each of them
2 nevi were excised, one being positive but the other neg-
ative for this mutation (data not shown). Others have
searched for germ-line mutations in the BRAF gene. Laud
et al (2003) sequenced the entire BRAF gene in melanoma-
prone families and could not identify BRAF germ-line mu-
tations as a risk factor for melanoma (Laud et al, 2003; Ca-
sula et al, 2004). In contrast, Meyer et al, found an
association between germ-line nucleotide polymorphisms
in BRAF with the occurrence of melanoma (Meyer et al,
2003b). With regard to somatic BRAF mutations, they can
be also seen in completely unsuspicious dermal nevi (Pol-
lock et al, 2003; Yazdi et al, 2003), which would contradict
the assumption that nevi with BRAF mutations are indeed
precursors of melanoma. We have identified, however, a
high frequency of BRAF mutations in rapidly changing me-
lanocytic lesions, which in adults are always an alarm signal
for melanoma. Thus, today the biological relevance of
BRAFV599E mutations still remains open; the possibility that
nevi with BRAF mutations are indeed at risk to develop into
melanoma is still not ruled out completely (Meyer et al,
2003a).
Second question: is the BRAF mutation the cause of the
sudden onset of growth in melanocytic lesions? In vitro ex-
periments found an increased transformatory potential of
Table Ia. Lesion size at the initial and follow-up visit
Mean  SEM Initial (mm2) Follow-up (mm2) % increase Follow-up (months)
Lesions with growth and/or
structural changes at follow-up
BRAFwt (n¼ 29) 38  6 46  7 20  4 11  2
BRAFV599E (n¼20) 44  8 54  7 35  9 12  2
Lesions without changes BRAFwt (n¼ 33) 37  5 38  5 3  2 11  1
BRAFV599E (n¼2) 47 50 6 8
Not significant.
po0.01 compared to changed lesions.
Table Ib. Distribution of BRAFV599E mutation within melanocytic lesions
Lesions with growth and/or structural changes at follow up
Lesions without changes
Melanoma (n¼ 24) Nevi (n¼25) Nevi (n¼35)
BRAFwt (n¼ 9) BRAFV599E (n¼ 15) BRAFwt (n¼20) BRAFV599E (n¼ 5) BRAFwt (n¼ 33) BRAFV599E (n¼2)
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cells bearing BRAF mutations, which suggests that this
mutation is responsible for the increased growth in vivo. If
so, how is growth stop accomplished in benign lesions?
From clinical observations we know that inconspicuous nevi
may show rapid growth followed by a growth stop after a
period of time in early childhood. In adults rapid and tem-
porarily limited growth of melanocytic lesions can be ob-
served during pregnancy. In both cases, we assume that the
temporarily increased release of growth factors is respon-
sible for this effect, but details are unknown. In case of
the BRAF mutation, the situation would be different. If this
mutation is responsible for growth in melanocytic lesions,
growth stop would require either the elimination of BRAF-
mutated cells or inactivation of the mutation. This could be
accomplished by, e.g., an immune response. Lymphocytic
infiltrates are commonly seen in nevi, but their significance
in correlation with BRAF-mutated cells has yet not been
investigated (in our series no correlation was observable,
data not shown). The sudden occurrence of apoptosis of
Table Ic. The BRAFV599E mutation is significantly associated
with growth of melanocytic lesions
Growing
lesions
(n¼36)
Lesions with
structural
changes (n¼ 13)
Lesions without
changes during
follow-up
(n¼ 35)
BRAFwt 55% 69% 94%
BRAFV599E 45% 31% 6%
Odds:  13  7 po0.001
initial lesion follow-up
1a b
3a b
4a b
2a b
1 mm 
1 mm 
1 mm 
1 mm 
Figure 1
DELM pictures from four representative melanocytic lesions. Pan-
els 1a–4a show the lesions at the initial visit; 1b–4b show the respective
follow-up pictures. (1) Melanoma with structural changes (arrowheads),
as an atypical pigment network, irregular streaks and regression struc-
tures after 9 mo. (2) Melanoma with extensive asymmetrical growth
within 13 months (arrowheads). (3) Nevus with no apparent changes
within the follow-up period of 14 months. (4) Nevus, which increased in
size during a 9 mo follow-up. Scale bar¼1 mm.
Figure2
BRAF genotyping of melanocytic lesions. (a) The photograph shows
results from amplification reactions with primer pairs detecting the
mutated allele (lanes 1–4) or the wild-type (lanes 5–8) of the BRAF gene.
In lanes 1 and 5, SKMel-28 cells (containing both the mutated and
wildtype allele) were amplified as a positive control, in lanes 2 and 6,
water was used as a negative control. In lanes 3 and 7, a heterocygous
sample from a melanocytic lesion containing both mutated and wild-
type alleles and in lanes 4 and 8, a patient sample containing only wild-
type alleles are shown. (b, c) Sequence electropherograms of two dif-
ferent samples are shown. Nucleotide 300 in b is a ‘‘W’’ (‘‘A’’ and ‘‘T’’
according to the IUB code), indicating a heterozygous sample with one
wild-type and one mutated allele, whereas in c, nucleotide 300 is a ‘‘T’’,
indicating a wild-type sample.
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BRAF-mutated cells would be another explanation. In vitro,
silencing of the BRAFV599E mutation leads to apoptosis of
BRAFV599E cells, but this has yet not been investigated
in vivo (Hingorani et al, 2003).
In conclusion, our data identified a correlation of lesion
growth with the presence of BRAFV599E mutation, which
supports the assumption made in vitro that this mutation
induces cell proliferation. This raises the question if the
V599E mutation determines lesions at risk developing into
melanoma and if not, what is the mechanisms controlling
growth stop in benign lesions.
Materials and Methods
DELM and histopathological examination During 1997–2001,
we identified a total of 324 lesions by DELM (MoleMaxII, Derma
Instruments, Vienna, Austria) (Kittler et al, 2000), which showed a
change of structure and/or size during the follow-up visit. All these
lesions were clinically unsuspicious at the initial visit. All 324 le-
sions were excised and examined by histology; 24 of 324 were
classified as melanoma in situ or thin melanoma with a Breslow
index of mean 0.42  0.09 mm. The remaining 300 lesions were
benign by histology. For this study we used material from these 24
melanomas and from 25 nevi randomly selected from the 300 nevi
described above (mean follow-up period was 12 months, mean
patient age was 46  15 y, range 20–74 y). As a control we ran-
domly selected 35 additional nevi, which did not show any chang-
es in size or structure during the follow-up period of mean 11
months and which were excised on request of the patients, mostly
for cosmetical reasons. This retrospective study was approved by
the Institutional Review Board of the Medical University of Vienna
and conducted according to Declaration of Helsinki Principles. For
excisions, patients gave written informed consent.
For morphometric analyses of dermatoscopic images, image
analysis software was used which was designed on the basis of
the Mathlab image-processing toolbox (Mathworks, Natick, Mas-
sachusetts). After interactive segmentation of the lesions from the
background, area calculations were performed automatically by
the software.
Typing of BRAF mutations For DNA typing of the most common
mutation in the BRAF gene that leads to a V599E mutation, a PCR
was established with either the primer pair BRAFSSP-AMP-A (50-
AAA ATA GGT GAT TTT GGT CTA GCT ACA GA-30 and BRAFSSP-
REV-A (50-AGA CAA CTG TTC AAA CTG ATG GGA-30) detecting
the mutated allele or the primer pair BRAFSSP-AMP-T (50-ACT
GTT TTC CTT TAC TTA CTA CAC-30) and BRAFSSP-REV-T (50-ACC
CAC TCC ATC GAG ATT TCA-30) detecting the wild-type allele. The
size of the amplification product of the mutated allele was 72 and
107 bp of the wild-type allele, respectively. This system was val-
idated with control cells containing BRAFwt (human umbilical vein
endothelial cells, HUVEC) or BRAFV599E (human melanoma cell line
SKMel-28) alleles. The specificity of the PCR with the allele specific
primers was further confirmed by sequencing the control samples
and in selected samples from the patients. For sequencing, DNA
samples were amplified with the primer pair BRAFSeqAMP790 (50-
ACT GTT TTC CTT TAC TTA CTA CAC C-30) and BRAFSeqREV (50-
TCT GGT GCC ATC CAC AAA AT-30). The amplification products
were directly sequenced using the sequencing primers BRA-
FSeqAMP794 (50-TTT CCT TTA CTT ACT ACA CCT CAG-30) and
BRAFSeq3 (50-GGT GCC ATC CAC AAA ATG GA-30).
Sample preparation for DNA typing was performed by macro-
dissecting the selected paraffin-embedded melanocytic lesions.
Due to the small size of the lesions (mean 4–5 mm in diameter), a
microdissection was not possible. For DNA extraction, 10 sections
with a thickness of 10 mm each were used per lesion. Paraffin was
removed by repeated extractions with xylol and ethanol. After a
final ethanol wash, samples were dried and soaked in 200 mL PBS.
DNA was then extracted with a QIAmp DNA blood mini extraction
kit (Qiagen, Hilden, Germany) according to the recommendations
of the manufacturer. The PCR reaction buffer contained 10 mM Tris
(pH¼ 8), 100 mM KCl and 1.5 mM MgCl2, 0.2 mM dNTPs (Roche
Molecular Biochemicals, Vienna, Austria), 0.04 U Taq Polymerase
(AmpliTaq, Perkin Elmer, Wellesley, Massachusetts) and 3.2 nM of
the respective primers. The PCR was performed in a Perkin Elmer
9700 thermal cycler. After an initial denaturation step at 921C for 2
min, 37 cycles were performed with denaturation at 941C for 20 s,
annealing at 63.51C for 30 s and extension at 721C for 30 s. The
PCR ended with a final extension step at 721C for 4 min. The
amplification product was visualized under UV light after agarose
gel electrophoresis and staining with ethidium bromide.
Statistical analysis Comparison of proportions was performed
with w2 tests or Fisher’s exact tests as appropriate. Statistical
analyses were performed using SPSS 10.0 (SPSS, Chicago. Illi-
nois) software package. All given p-values are two-tailed and a p-
value of o0.05 was regarded to indicate statistical significance.
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